A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of OrallyAdministered ALS-008176 Regimens in Infants and Children Aged 1 to 36 Months Hospitalized with Respiratory Syncytial Virus
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Lumicitabine (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development; Janssen-Cilag
- 07 Mar 2018 Status changed from recruiting to suspended due to pending release new drug supply
- 02 Jan 2018 Planned End Date changed from 26 May 2019 to 30 Apr 2019.
- 15 Dec 2017 Status changed from not yet recruiting to recruiting.